|
Friday 4th July 2003 |
Text too small? |
Chairman Jim Guthrie said from Dunedin yesterday that the death on Monday of director and significant shareholder Howard Paterson follows closely after the cancer diagnosis and subsequent treatment of founder Dr Corran McLachlan.
"Directors, shareholders and staff are devastated by Howard's sudden death," he said.
"Corrie is undergoing treatment and is not expected to be on deck for some time."
Mr Guthrie said the best way they could "keep faith with the vision of Mr Paterson and Dr McLachlan was to continue with the work they began."
Mr Guthrie said A2 Corporation's European directors would be travelling to New Zealand shortly to help the board review the company's future options.
"We are fortunate that we can call on the services of some very talented people here and overseas," he said. "Despite these recent tragic occurrences A2 Corporation is strongly positioned to build upon the foundation laid down by Howard and Corrie."
A2 Corporation was founded in 2000 to commercialise research relating to milk proteins. Its licensees have recently released a range of milk products on the New Zealand and Australian markets.
No comments yet
KMD strengthens balance sheet with debt refinance
GXH - Green Cross Health Limited - Annual Shareholders' Meeting
VGL - Cineplexx Europe signs to Operational Excellence
STU - Steel & Tube - Director Resignation - Steve Reindler
Ryman Healthcare Limited Notice of Meeting 2026
Spark New Zealand FY26 Results Announcement Date
OCA - Oceania bond offer - interest rate set
VNT - Appointment of Managing Director and Group CEO of Ventia
ATM - a2MC declares $300 million special dividend
June 25th Morning Report